HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 279, Issue 21, 22124-22130, May 21, 2004

This Article Full Text Full Text (PDF) All Versions of this Article: 279/21/22124    most recent M400908200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bougie, I. Articles by Bisaillon, M. Search for Related Content PubMed PubMed Citation Articles by Bougie, I. Articles by Bisaillon, M. Social Bookmarking                      What's this?

The Broad Spectrum Antiviral Nucleoside Ribavirin as a Substrate for a Viral RNA Capping Enzyme^*

Isabelle Bougie and Martin Bisaillon, A New Investigator Scholar from the Canadian Institutes for Health Research

From the Département de Biochimie, Faculté de Médecine, Université de Sherbrooke, Sherbrooke, Québec J1H 5N4, Canada

The broad spectrum antiviral nucleoside ribavirin displays activity against a variety of RNA and DNA viruses. A number of possible mechanisms have been proposed during the past 30 years to account for the antiviral activity of ribavirin, including the possibility that ribavirin might have a negative effect on the synthesis of the RNA cap structure of viral RNA transcripts. In the present study, we investigated the possibility that ribavirin can directly serve as a substrate for the vaccinia virus RNA capping enzyme. We demonstrate that ribavirin triphosphate can be used as a substrate by the capping enzyme and can form a covalent ribavirin monophosphate-enzyme intermediate reminiscent of the classical GMP-enzyme intermediate. Furthermore, our data indicate that ribavirin monophosphate can be transferred to the diphosphate end of an RNA transcript to form the unusual RpppN structure. Finally, we provide evidence that RNA transcripts that possess ribavirin as the blocking nucleoside are more stable than unblocked transcripts. However, in vitro translation assays indicate that RNA transcripts blocked with ribavirin are not translated efficiently. Our study provides the first biochemical evidences that ribavirin can directly interact with a viral capping enzyme. The ability of a purified RNA capping enzyme to utilize ribavirin as a substrate has not been previously documented and has implications for our understanding of the catalytic mechanisms of RNA capping enzymes. The biological implications of these findings for the proposed ribavirin-mediated inhibition of capping are discussed.

Received for publication, January 28, 2004 , and in revised form, March 15, 2004.

^* This work was supported by grants from both the Canadian Institutes for Health Research (CIHR) and Fonds de la Recherche en Santé du Québec (FRSQ). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Dept. de Biochimie, Faculté de Médecine, Université de Sherbrooke, 3001 12th Ave., Sherbrooke, Québec, Canada, J1H 5N4. Tel.: 819-564-5227; Fax: 819-564-5340; E-mail: Martin.Bisaillon{at}USherbrooke.ca.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. F. Souliere, J.-P. Perreault, and M. Bisaillon Magnesium-binding studies reveal fundamental differences between closely related RNA triphosphatases Nucleic Acids Res., February 2, 2008; 36(2): 451 - 461. [Abstract] [Full Text] [PDF]

				P. Leyssen, E. De Clercq, and J. Neyts The Anti-Yellow Fever Virus Activity of Ribavirin Is Independent of Error-Prone Replication Mol. Pharmacol., April 1, 2006; 69(4): 1461 - 1467. [Abstract] [Full Text] [PDF]

				B. WESTMAN, L. BEEREN, E. GRUDZIEN, J. STEPINSKI, R. WORCH, J. ZUBEREK, J. JEMIELITY, R. STOLARSKI, E. DARZYNKIEWICZ, R. E. RHOADS, et al. The antiviral drug ribavirin does not mimic the 7-methylguanosine moiety of the mRNA cap structure in vitro RNA, October 1, 2005; 11(10): 1505 - 1513. [Abstract] [Full Text] [PDF]

				Y. YAN, Y. SVITKIN, J. M. LEE, M. BISAILLON, and J. PELLETIER Ribavirin is not a functional mimic of the 7-methyl guanosine mRNA cap RNA, August 1, 2005; 11(8): 1238 - 1244. [Abstract] [Full Text] [PDF]

				J. Z. Wu, G. Larson, H. Walker, J. H. Shim, and Z. Hong Phosphorylation of Ribavirin and Viramidine by Adenosine Kinase and Cytosolic 5'-Nucleotidase II: Implications for Ribavirin Metabolism in Erythrocytes Antimicrob. Agents Chemother., June 1, 2005; 49(6): 2164 - 2171. [Abstract] [Full Text] [PDF]